InDex Pharmaceuticals out-licenses cobitolimod to Viatris Japan

1 June 2023

Swedish immunology company InDex Pharmaceuticals InDex Pharmaceuticals has signed a license agreement with the Japanese subsidiary of Viatris (Nasdaq: VTRS) to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis, under an agreement worth up to $50 million including milestones.

Cobitolimod is a TLR9 agonist which is being evaluated in the global Phase III program CONCLUDE, as a novel treatment for moderate to severe ulcerative colitis.

Under the terms of the agreement, Viatris Japan will pay InDex an upfront fee of $10 million for the exclusive rights to commercialize cobitolimod in Japan. In addition, InDex is eligible for development and sales milestone payments of up to $40 million. Viatris Japan will also pay up to double-digit percentage royalties based on its net sales for the product in Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK